Limits...
Expression of lymphatic markers and lymphatic growth factors in psoriasis before and after anti-TNF treatment.

Moustou AE, Alexandrou P, Stratigos AJ, Giannopoulou I, Vergou T, Katsambas A, Antoniou C - An Bras Dermatol (2014 Nov-Dec)

Bottom Line: VEGF-C expression on lymphatic vessels diminished after treatment with etanercept.Remodeling of lymphatic vessels possibly occurs during psoriatic lesion development, parallel to blood vessel formation.The exact role of this alteration is not yet clear and more studies are necessary to confirm these results.

View Article: PubMed Central - PubMed

Affiliation: Medical School, University of Athens, Athens, Greece.

ABSTRACT

Background: Angiogenesis is an early stage of psoriatic lesion development, but less is known about lymphagiogenesis and its role in the development of psoriasis.

Objective: To examine the expression of specific lymphatic markers and lymphatic growth factors in untreated psoriatic skin, in the unaffected skin of patients and skin of healthy volunteers, as well as their alteration after treatment with an anti-TNF agent.

Methods: Immunohistochemistry for the lymphatic markers D2-40 and LYVE-1, in addition to the VEGF-C and VEGF-D growth factors, was performed in the skin biopsies of psoriatic lesions and adjacent non-psoriatic skin of 19 patients before and after treatment with etanercept, as well as in the skin biopsies of 10 healthy volunteers.

Results: The expressions of D2-40, VEGF-C and VEGF-D on lymphatic vessels underwent statistically significant increases in untreated psoriatic skin compared with non-lesional skin, in contrast to LYVE-1, which did not involve significant increase in expression in psoriatic skin. VEGF-C expression on lymphatic vessels diminished after treatment with etanercept. Moreover VEGF-C and VEGF-D staining on fibroblasts presented with higher expression in lesional skin than in non-lesional adjacent skin.

Conclusion: Remodeling of lymphatic vessels possibly occurs during psoriatic lesion development, parallel to blood vessel formation. The exact role of this alteration is not yet clear and more studies are necessary to confirm these results.

Show MeSH

Related in: MedlinePlus

Granular VEGF-D staining on LV wall (blue arrows). VEGF-D is also expressed infibroblasts with intensity on psoriatic skin (red arrows). A:psoriatic skin before treatment, B: psoriatic skin after treatment,C: normal skin of patient. Original magnification x200
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4230657&req=5

f04: Granular VEGF-D staining on LV wall (blue arrows). VEGF-D is also expressed infibroblasts with intensity on psoriatic skin (red arrows). A:psoriatic skin before treatment, B: psoriatic skin after treatment,C: normal skin of patient. Original magnification x200

Mentions: The evaluation of LVs according to VEGF-D staining revealed a statisticallysignificantly increased LV density, expressing VEGF-D in psoriatic skin compared withnon-psoriatic skin of patients before treatment (P<0.001). This difference did notremain after treatment (P=0.365). In addition, treatment did not alter the number oflymphatics in psoriatic skin (P=0.384), as per VEGF-D staining. Moreover, we did notfind any difference between LVs in non-lesional skin of untreated patients and those inskin of healthy volunteers (P=0.216) - (Table2). VEGF-D staining in fibroblasts was higher in psoriatic skin thannon-psoriatic skin before treatment (P=0.004) and after treatment (P=0.011), thoughthere was no difference between psoriatic skin before and after treatment (P=0.813) andno difference between non-lesional skin before treatment and the skin of healthyvolunteers (P=0.132) - (Figure 4).


Expression of lymphatic markers and lymphatic growth factors in psoriasis before and after anti-TNF treatment.

Moustou AE, Alexandrou P, Stratigos AJ, Giannopoulou I, Vergou T, Katsambas A, Antoniou C - An Bras Dermatol (2014 Nov-Dec)

Granular VEGF-D staining on LV wall (blue arrows). VEGF-D is also expressed infibroblasts with intensity on psoriatic skin (red arrows). A:psoriatic skin before treatment, B: psoriatic skin after treatment,C: normal skin of patient. Original magnification x200
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4230657&req=5

f04: Granular VEGF-D staining on LV wall (blue arrows). VEGF-D is also expressed infibroblasts with intensity on psoriatic skin (red arrows). A:psoriatic skin before treatment, B: psoriatic skin after treatment,C: normal skin of patient. Original magnification x200
Mentions: The evaluation of LVs according to VEGF-D staining revealed a statisticallysignificantly increased LV density, expressing VEGF-D in psoriatic skin compared withnon-psoriatic skin of patients before treatment (P<0.001). This difference did notremain after treatment (P=0.365). In addition, treatment did not alter the number oflymphatics in psoriatic skin (P=0.384), as per VEGF-D staining. Moreover, we did notfind any difference between LVs in non-lesional skin of untreated patients and those inskin of healthy volunteers (P=0.216) - (Table2). VEGF-D staining in fibroblasts was higher in psoriatic skin thannon-psoriatic skin before treatment (P=0.004) and after treatment (P=0.011), thoughthere was no difference between psoriatic skin before and after treatment (P=0.813) andno difference between non-lesional skin before treatment and the skin of healthyvolunteers (P=0.132) - (Figure 4).

Bottom Line: VEGF-C expression on lymphatic vessels diminished after treatment with etanercept.Remodeling of lymphatic vessels possibly occurs during psoriatic lesion development, parallel to blood vessel formation.The exact role of this alteration is not yet clear and more studies are necessary to confirm these results.

View Article: PubMed Central - PubMed

Affiliation: Medical School, University of Athens, Athens, Greece.

ABSTRACT

Background: Angiogenesis is an early stage of psoriatic lesion development, but less is known about lymphagiogenesis and its role in the development of psoriasis.

Objective: To examine the expression of specific lymphatic markers and lymphatic growth factors in untreated psoriatic skin, in the unaffected skin of patients and skin of healthy volunteers, as well as their alteration after treatment with an anti-TNF agent.

Methods: Immunohistochemistry for the lymphatic markers D2-40 and LYVE-1, in addition to the VEGF-C and VEGF-D growth factors, was performed in the skin biopsies of psoriatic lesions and adjacent non-psoriatic skin of 19 patients before and after treatment with etanercept, as well as in the skin biopsies of 10 healthy volunteers.

Results: The expressions of D2-40, VEGF-C and VEGF-D on lymphatic vessels underwent statistically significant increases in untreated psoriatic skin compared with non-lesional skin, in contrast to LYVE-1, which did not involve significant increase in expression in psoriatic skin. VEGF-C expression on lymphatic vessels diminished after treatment with etanercept. Moreover VEGF-C and VEGF-D staining on fibroblasts presented with higher expression in lesional skin than in non-lesional adjacent skin.

Conclusion: Remodeling of lymphatic vessels possibly occurs during psoriatic lesion development, parallel to blood vessel formation. The exact role of this alteration is not yet clear and more studies are necessary to confirm these results.

Show MeSH
Related in: MedlinePlus